Key Takeaways:
A securities class action lawsuit has been filed against Gossamer Bio, Inc. (GOSS) after the company’s stock price fell by approximately 80% following the failure of its Phase 3 PROSERA clinical trial.
The lawsuit, filed by Hagens Berman, seeks to represent investors who acquired Gossamer securities between June 16, 2025, and February 20, 2026, according to a statement from the law firm.
The legal action follows Gossamer’s announcement on February 23, 2026, that the PROSERA study's top-line results did not meet the primary endpoint, which was the change from baseline in six-minute-walk distance at week 24.
The sharp decline in share price reflects the significant setback for the company, as the trial's failure undermines a key asset in its clinical pipeline and exposes it to substantial legal costs.
The combination of a late-stage clinical failure and a securities class action presents a major challenge to Gossamer Bio's long-term prospects. Investors will be watching for the company's response to the lawsuit and any updates on its remaining clinical programs.
This article is for informational purposes only and does not constitute investment advice.
